NEW YORK (360Dx) – Genomica and HuaSin on Monday announced that they have entered an agreement by which HuaSin obtained exclusive rights to develop and produce a fully automated HPV genotyping assay platform that uses Genomica's technology.

Financial and other terms of the deal were not disclosed.

Guangzhou, China-based HuaSin has commenced a registration process with the China Food and Drug Administration, and subject to regulatory approval anticipates launching the platform in China in 2021.